HCM HUTCHMED (China) Limited

2.831USD215.00 GBp · LSE-0.92%Mkt Cap: 2.46B USDP/E: 215.00

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …

Institutional holders10 on file

Key Statistics

Company
Market Cap2.46B USD
Enterprise Value813.98M USD
Revenue (TTM)549.12M USD
Gross Profit212.16M USD
Net Income (TTM)456.91M USD
Revenue/Share0.64 USD
Last Price2.831 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINKYG4672N1198
Valuation
P/E (Trailing)215.00
P/E (Forward)41.41
PEG—
EV/EBITDA-30.13
EV/Revenue1.48
P/S3.40
P/B1.98
EPS (TTM)0.01 USD
EPS (Forward)0.05 USD
52W Range
1.98273% of range3.147
52W High3.147 USD
52W Low1.982 USD
Profitability
Gross Margin38.68%
Oper. Margin-6.33%
EBITDA Margin-3.74%
Profit Margin83.30%
ROE36.91%
ROA26.06%
ROIC—
ROCE-2.48%
Growth
Revenue Growth0.20%
Earnings Growth-96.50%
Cash Flow & Leverage
Operating CF-64.66M USD
CapEx (TTM)24.15M USD
FCF Margin-3.44%
FCF Yield-0.77%
Net Debt-1.28B USD
Net Debt/EBITDA62.49
Net Debt/FCF—
Balance Sheet
Debt/Equity0.08
Current Ratio5.64
Quick Ratio5.45
Book Value/Sh1.08 USD
Cash/Share1.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split10:1
Split DateMay 30, 2019
Analyst Consensus
Rating—
Target (Mean)4.865 USD
Upside (mean)+71.8%
Target Range3.435 USD – 7.069 USD
3.435+71.8% to mean7.069
# Analysts6
Ownership
Shares Out.869.07M
Float528.06M
Insiders38.80%
Institutions19.73%
Technical
SMA 502.796 (+1.2%)
SMA 2002.582 (+9.7%)
Beta0.50
S&P 52W Chg12.08%
Avg Vol (30d)20.29K
Avg Vol (10d)26.02K
Technical Indicators
RSI (14)49.3
MACD2.8155
MACD Signal2.8247
MACD Hist.-0.0092
BB Upper3.079 USD
BB Middle2.823 USD
BB Lower2.568 USD
BB Width18.11%
ATR (14)0.1515 USD
Vol Ratio (20d)2.26x

About HUTCHMED (China) (LON: HCM)

›

HUTCHMED (China) (LON: HCM) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,790 employees.

The shares were at 215.00 GBp on 19 November 2026, down 4.2% over 52 weeks. Its 52-week range is 150.48 GBp to 239.00 GBp: the price is 10.0% below the high and 42.9% above the low.

At a market capitalisation of 1.87B GBP, it trades at 215.0 times trailing earnings and 41.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 770% for HCM.

HUTCHMED (China) reports return on equity of 36.9%, an operating margin of -6.3% and flat revenue year over year.

It holds more cash than debt, a net cash position of 1.28B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock; their mean price target of 369.47 GBp is 71.8% above the current price. The next earnings report is expected on 4 March 2027.